Literature DB >> 28450818

The Role of Regorafenib in Hepatocellular Carcinoma.

Catherine T Frenette1.   

Abstract

Entities:  

Year:  2017        PMID： 28450818      PMCID： PMC5402683     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

1.  Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.

Authors:  Scott M Wilhelm; Jacques Dumas; Lila Adnane; Mark Lynch; Christopher A Carter; Gunnar Schütz; Karl-Heinz Thierauch; Dieter Zopf
Journal:  Int J Cancer       Date:  2011-04-22       Impact factor: 7.396

Review 2.  Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.

Authors:  Elizabeth Manchen; Caroline Robert; Camillo Porta
Journal:  J Support Oncol       Date:  2011 Jan-Feb

3.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M Llovet; Richard S Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321

4.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

5.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321
  5 in total
  4 in total

Review 1.  Role of microRNAs in the development of hepatocellular carcinoma and drug resistance.

Authors:  Lucas Tricoli; Suresh Niture; Uche Chimeh; Habtom Ressom; Deepak Kumar
Journal:  Front Biosci (Landmark Ed)       Date:  2019-01-01

2.  New 3-Aryl-2-(2-thienyl)acrylonitriles with High Activity Against Hepatoma Cells.

Authors:  Eva Schaller; Andi Ma; Lisa Chiara Gosch; Adrian Klefenz; David Schaller; Nils Goehringer; Leonard Kaps; Detlef Schuppan; Andrea Volkamer; Rainer Schobert; Bernhard Biersack; Bianca Nitzsche; Michael Höpfner
Journal:  Int J Mol Sci       Date:  2021-02-24       Impact factor: 5.923

Review 3.  A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma.

Authors:  Angelica Singh; Sofia Zahid; Ilya Noginskiy; Timothy Pak; Soeb Usta; Marina Barsoum; Uqba Khan
Journal:  Curr Oncol       Date:  2022-09-08       Impact factor: 3.109

4.  Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma.

Authors:  Federica Ragusa; Nadia Panera; Silvia Cardarelli; Marco Scarsella; Marzia Bianchi; Stefano Biagioni; Mauro Giorgi; Anna Alisi; Mara Massimi
Journal:  Cancers (Basel)       Date:  2021-05-01       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.